EVOTEC, SENSYNE HEALTH, THE UNIVERSITY OF OXFORD, OSI, AND OUI CREATE NEW BRIDGE PARTNERSHIP “LAB10X” IN DIGITAL HEALTH

Hamburg, Germany and Oxford, UK, 24 Jun 2019

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that it has entered into a new strategic partnership with the British clinical AI technology company Sensyne Health plc (LSE:SENS) (“Sensyne”), the University of Oxford, Oxford University Innovation Ltd (“OUI”, the university's research commercialisation company), and Oxford Sciences Innovation (“OSI”, the world's largest IP investment company dedicated to a single university) to fund a new BRIDGE called LAB10x.